Stem Cell Breakthrough: Could An Engineered Spinal Cord Help Paralysed People Walk Again?

Written by Editor

Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice, diagnosis or a recommendation for treatment. The technology discussed is experimental and has not yet been proven to restore walking in humans. Results achieved in laboratory animals cannot be assumed to produce the same results in people. Anyone living with paralysis or spinal cord injury should discuss treatment, rehabilitation and participation in legitimate clinical research with suitably qualified medical professionals. People should also be cautious of private clinics claiming that existing stem-cell treatments can cure paralysis simply because promising experimental research has been reported.

Could Professor Tal Dvir’s Engineered Spinal Cord Help Paralysed People Walk Again?

Tel Aviv University research is moving towards the first potential human implantation of a personalised, lab-grown spinal cord, after remarkable results restored walking in animals with acute and chronic paralysis.

Scientists at Tel Aviv University in Israel are moving closer to something that, not very long ago, would have sounded like science fiction: creating personalised spinal cord tissue from a patient’s own cells and implanting it into an injured spinal cord in an attempt to restore lost neurological function.

The research is led by Professor Tal Dvir, whose work encompasses tissue engineering, regenerative medicine, stem cells and three-dimensional biological implants. His laboratory has been developing a method of creating functional neuronal networks capable of acting as a biological bridge across damaged areas of the spinal cord.

Importantly, however, headlines suggesting that scientists can already “make paralysed people walk again” need qualification.

They have made paralysed laboratory animals walk again.

Whether the treatment can safely and effectively achieve something similar in humans is precisely what researchers now hope to discover.

And as of August 2026, that journey has moved significantly closer to its first potential human treatment.

Who Is Professor Tal Dvir?

Professor Tal Dvir is a researcher at Tel Aviv University’s Shmunis School of Biomedicine and Cancer Research and works extensively in regenerative medicine and tissue engineering.

His research interests include creating three-dimensional neuronal networks for the regeneration of the brain and spinal cord. His work has also involved 3D bioprinting and engineered cardiac tissue.

In January 2026, Tel Aviv University announced that Professor Dvir had been elected a Fellow of the US National Academy of Inventors, recognising work including 3D bioprinting, regenerative medicine and spinal cord implants.

Professor Dvir is also Chief Scientist of biotechnology company Matricelf, which is attempting to translate the university research into a treatment that could eventually be used clinically.

What Has Professor Dvir’s Team Created?

Although the research is often described broadly as “stem cell therapy“, it is considerably more sophisticated than simply injecting stem cells into someone’s spinal cord.

The idea is to create a personalised three-dimensional neural implant.

Researchers take cells from the patient and reprogramme them into what are known as induced pluripotent stem cells, or iPSCs.

These are adult cells that have effectively been reset into a state in which they can develop into other specialised types of cells.

Material obtained from the patient’s own tissue can meanwhile be processed into a biological hydrogel.

The reprogrammed cells are placed inside this personalised biological environment and encouraged to develop into spinal cord neurons and organised neuronal networks.

Instead of implanting a collection of individual stem cells, researchers therefore aim to produce an actual piece of engineered, three-dimensional neural tissue.

The intention is for this tissue to be implanted into the damaged section of the spinal cord.

Why Is Spinal Cord Injury So Difficult to Repair?

The spinal cord acts like an extremely sophisticated communication highway between the brain and the rest of the body.

Signals generated by the brain travel along nerve pathways in the spinal cord to control movement and numerous bodily functions.

A severe spinal cord injury can disrupt those pathways.

Unlike skin, for example, damaged spinal cord tissue has very limited ability to regenerate itself. Scar tissue and other biological changes following an injury can also create an environment that makes neuronal regeneration extremely difficult.

This is particularly challenging in chronic spinal cord injuries, where considerable time has passed since the original trauma.

The peer-reviewed research behind Professor Dvir’s approach specifically examined whether engineered human neuronal networks could help regenerate an injured spinal cord during this chronic stage.

Could an Engineered Spinal Cord Bridge the Damage?

That is essentially the theory.

Imagine an electrical cable that has been severed.

Electricity cannot reach the other end because the connection has been interrupted.

Professor Dvir has previously used a similar analogy when explaining spinal cord injury: neurological signals cannot travel properly beyond the damaged section.

The engineered tissue is intended to act as a biological bridge, providing neuronal networks capable of integrating with the patient’s nervous system and potentially allowing signals to cross an area where the normal pathway has been destroyed.

If successful, this would represent a fundamentally different approach from simply helping someone compensate for an injury.

The ambition is regeneration and reconnection.

The Animal Experiments Produced Remarkable Results

This is where the research attracted international attention.

In experiments reported by Tel Aviv University in 2022, engineered human spinal cord tissue was implanted into laboratory models of both recent and long-term paralysis.

According to the university:

100% of the acute-injury laboratory models regained walking ability, and
approximately 80% of those with chronic paralysis regained walking ability.

The chronic injury model was particularly significant because it was designed to represent an injury that had existed for a substantial period rather than one treated immediately after trauma.

The research was published in the peer-reviewed journal Advanced Science under the title Regenerating the Injured Spinal Cord at the Chronic Phase by Engineered iPSCs-Derived 3D Neuronal Networks.

The scientific study reported improved structural and functional outcomes following both acute and chronic spinal cord injuries and described the technology as a potential way of eventually rewiring an injured human spinal cord.

These findings are extraordinary.

But there is an important distinction:

An animal result is not a human cure.

Many treatments that work remarkably well in laboratory models subsequently prove less effective, ineffective or unsafe when tested in humans.

That is why human trials are so important.

What Is Happening in 2026?

There has been a significant new development.

On 19 August 2026, Tel Aviv University announced that the project had moved another step towards potential human implantation.

Matricelf has entered into a collaboration with the Loewenstein Rehabilitation Medical Centre to begin identifying and assessing potential patients with spinal cord injuries.

Blood samples from suitable consenting candidates are expected to be used to begin producing their personalised neural implants.

Producing an individual implant takes several months.

According to the latest Tel Aviv University announcement, if scientific, manufacturing and regulatory requirements proceed as intended, the first potential treatment could take place during the first half of 2027.

That would represent the first attempted implantation of this engineered spinal cord technology in a person with paralysis.

Has the Human Trial Already Been Approved?

This requires some careful explanation.

Earlier Tel Aviv University reporting stated that preliminary approval had been obtained for compassionate-use treatment involving eight patients.

However, the university’s 19 August 2026 update makes an important distinction.

It states that identifying patients and beginning preparations does not constitute final approval to begin a clinical trial or to perform the implantation.

Treatment can proceed only after the remaining scientific and regulatory requirements have been satisfied and final authorisation has been obtained from the Israeli Ministry of Health.

Therefore, it would currently be misleading to say that humans have already been treated successfully.

They have not.

The research is approaching that stage.

Why Use the Patient’s Own Cells?

One particularly interesting part of this technology is its personalised nature.

In conventional transplantation, one of the major problems is that the recipient’s immune system may recognise transplanted tissue as foreign and attack it.

Professor Dvir’s strategy attempts to reduce this problem by producing the neural implant from biological material derived from the individual patient.

This is known as an autologous approach.

The hope is that a personalised implant will integrate more naturally with the patient’s body and reduce the likelihood of rejection.

However, reduced risk does not mean zero risk.

Any experimental cell-based treatment involving neurological surgery requires extensive safety testing and long-term follow-up.

What Could the Risks Be?

Regenerative medicine has enormous potential, but creating living tissue from reprogrammed cells and implanting it into the human nervous system presents substantial scientific challenges.

Researchers will need to establish whether the cells develop and behave as intended; whether the implant integrates successfully with surrounding tissue; whether meaningful neurological connections develop; whether improvements last; and whether unexpected cell growth, inflammation, infection, neurological deterioration or other complications occur.

There is also the question of how much recovery may be possible.

Restoring a limited amount of sensation or voluntary movement would already be medically significant, even if someone did not regain completely independent walking.

Success should therefore not be viewed as simply “walking versus not walking.”

Spinal cord injury affects people very differently, and meaningful improvements might include increased movement, greater trunk control, improved independence or other neurological functions.

Not Every Paralysed Person Has the Same Injury

The word paralysis covers a huge spectrum of circumstances.

A spinal cord can be completely or partially injured at different anatomical levels and through different mechanisms.

Some people retain sensory pathways. Others retain limited movement. Some injuries involve the cervical spinal cord and cause tetraplegia, while lower injuries may result primarily in paraplegia.

There can also be major differences between traumatic spinal cord injury and paralysis arising from neurological diseases, stroke, congenital conditions or other causes.

Consequently, even if Professor Dvir’s treatment proves successful, it cannot currently be assumed that every form of paralysis will be treatable.

Clinical research will have to establish which patients are suitable, what injuries respond best and at what stage after injury treatment is most effective.

A Word of Caution About “Stem Cell Cures”

Research of this magnitude inevitably creates hope.

Unfortunately, hope can also be exploited.

There are clinics around the world advertising various forms of “stem cell therapy” to people living with serious disabilities and incurable diseases, sometimes for extremely large sums of money.

Professor Dvir’s research should not be interpreted as evidence that commercially advertised stem-cell injections elsewhere have suddenly been proven effective.

They are not the same treatment.

This Tel Aviv University technology involves complex cell reprogramming, tissue engineering, personalised biomaterials, development of organised neuronal networks, surgical implantation and regulatory oversight.

People should be extremely cautious of anyone using headlines about legitimate university research to sell an unrelated, unproven treatment.

Disability, Hope and the Language of a “Cure”

There is another important dimension to this story.

Scientific research that could restore neurological function deserves excitement and investment, and people living with spinal cord injuries should have the right to pursue safe treatments if they choose.

At the same time, disability should not automatically be portrayed as a life waiting to be “fixed.”

Many wheelchair users live independent, successful and fulfilling lives.

Medical advances and disability rights should therefore progress together.

A future treatment capable of restoring movement should increase choice and independence rather than reinforce the idea that walking determines someone’s value or quality of life.

Accessible housing, employment, healthcare, transport, social care and protection from discrimination remain essential regardless of future medical breakthroughs.

Could This Eventually Change Medicine?

Potentially, yes.

If personalised engineered neural tissue can safely reconnect damaged spinal cord pathways in humans, the consequences could be profound.

It would also demonstrate something much wider: that scientists may be able to manufacture personalised living tissues capable of repairing structures that the human body cannot adequately regenerate itself.

Professor Dvir’s laboratory has already worked on engineered cardiac tissues as well as neuronal networks, illustrating how regenerative medicine is increasingly moving towards creating biological replacements rather than merely treating symptoms.

The implications could eventually extend far beyond spinal cord injury.

But the decisive test has yet to happen.

Conclusion

Professor Tal Dvir and researchers at Tel Aviv University have produced one of the most fascinating developments in modern regenerative medicine: personalised three-dimensional spinal cord tissue created using reprogrammed cells and biological material derived from the patient.

In laboratory models, the results have been remarkable, including the restoration of walking in animals with long-term paralysis.

The research has now moved from an experimental concept towards preparation for its first potential application in a human being.

As of August 2026, suitable patients are beginning to be identified, and personalised implants are being prepared, with researchers hoping the first treatment could potentially take place in the first half of 2027. Final regulatory approval is still required.

So can stem-cell technology make a paralysed person walk again?

In animals, this particular approach has already produced extraordinary recovery.

In humans, we do not know yet.

But we may be approaching the point at which scientists can finally begin answering one of regenerative medicine’s biggest questions.

And if even part of what has been achieved in the laboratory can eventually be reproduced safely in human patients, it could represent an extraordinary new chapter in the treatment of spinal cord injury.

Professor Tal Dvir and Tel Aviv University are developing personalised stem-cell spinal cord implants that restored walking in paralysed animals, with the first potential human treatment being prepared for 2027.